In what could turn out to be a game-changer in the field of oncology, Tata Institute in Mumbai which is known for treatment and research in Cancer has come up with a groundbreaking discovery that could prevent the recurrence of cancer in human body.
Doctors and researchers at the institute have developed a tablet which is not only capable of preventing the recurrence of cancer in human body but can also considerably reduce side effects caused by radiation and chemotherapy by 50%.
Affordable to all
The tablet is awaiting approval from Food Safety and Standards Authority of India (FSSAI). If it gets approved then it will be available in the market around June or July this year reportedly at a price of Rs 100 only, which makes it affordable for people from all strata of the society. This can be a major advantage given the cost of cancer treatment which is extremely high amounting to several lakhs and even cross and beyond everyone’s affordability.
Tablet named R+Cu
The tablet, named ‘R+Cu’, contains pro-oxidant tablets with resveratrol and copper, which generate oxygen radicals in the stomach. These radicals destroy chromatin particles released by dying cancer cells, preventing them from turning healthy cells cancerous. This process also inhibits the movement of cancer cells from one part of the body to another, known as ‘Metastases’.
Awaiting approval from FSSAI
According to Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, the medicine has been tested on rats for its effect on side effects and prevention and the results have been good.
“Tata doctors were working on this tablet for almost a decade. The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR (Tata Institute of Fundamental Research) scientists have applied to FSSAI to approve this tablet. After getting the approval, it will be available in the market from June-July. This tablet will help to a great extent in improving cancer treatment,” the senior cancer surgeon told NDTV in an interview.
Undergoing human trial
The medicine, which has already been tested on rats is currently undergoing human trial which will take about 5 years. It is especially effective for cancer of lungs pancreas and oral cavity.
